Business Context and Reporting Period
Company: MEDNAX, Inc. (formerly Pediatrix Medical Group, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Corporate Action: Effective December 31, 2008, the company completed a holding company formation transaction establishing MEDNAX, Inc. as the parent of Pediatrix. The NYSE trading symbol changed from "PDX" to "MD" in 2009.
Business Overview: MEDNAX is a leading provider of physician services, including neonatal, maternal-fetal, pediatric subspecialty, and anesthesia care. As of year-end 2008, the network comprised 1,274 affiliated physicians operating in 32 states and Puerto Rico. The company manages clinical activities in over 280 Neonatal Intensive Care Units (NICUs).
Key Financial Metrics
| Metric (in thousands) | 2008 | 2007 |
|---|---|---|
| Net Patient Service Revenue | $1,068,277 | $917,644 |
| Income from Operations | $242,029 | $220,900 |
| Net Income | $169,201 | $142,722 |
| Diluted EPS (Net Income) | $3.59 | $2.86 |
| Operating Margin | 22.7% | 24.1% |
| Cash and Cash Equivalents | $14,346 | $102,843 |
| Working Capital | ($32,224) | $99,239 |
| Line of Credit Borrowings | $139,500 | $0 |
| Days Sales Outstanding (DSO) | 50.2 days | 53.5 days |
Material Changes vs. Prior Period
- Revenue Growth: Net patient service revenue increased 16.4% to $1.1 billion. Approximately $122.8 million (81.5%) of this increase was attributable to acquisitions completed after December 31, 2006. Same-unit revenue increased 3.2%.
- Profitability: Net income increased 18.6% to $169.2 million. This includes a significant non-recurring gain of $22.0 million (net of tax) from the sale of the newborn metabolic screening laboratory business.
- Operating Margin Compression: Operating margin decreased from 24.1% to 22.7%. Management attributed this to lower volume in neonatal practices, the addition of lower-margin anesthesia and office-based services, and a shift in payor mix toward government-sponsored programs.
- Liquidity Shift: Cash and cash equivalents dropped significantly from $102.8 million to $14.3 million. The company moved from positive working capital to a deficit of $32.2 million, driven by $200 million in share repurchases, $274 million in acquisition payments, and the drawdown of a new $350 million line of credit.
- Payor Mix: The percentage of revenue from government payors remained stable at 26% of net revenue, but the gross amount billed to government programs increased to 55% on a same-unit basis, reflecting a shift toward lower-reimbursement government programs due to economic conditions.
Guidance, Outlook, and Risks
- Acquisition Strategy: The company plans to invest $70 million to $75 million in acquisitions in 2009, focusing on neonatal, maternal-fetal, and pediatric cardiology specialties, while continuing to pursue anesthesia practices.
- Economic Risks: Management highlighted the impact of the U.S. economic slowdown, including lower NICU patient volumes and a shift toward government-sponsored healthcare programs (Medicaid/Medicare), which reimburse at lower rates than commercial payors.
- Regulatory and Legal:
- Stock Option Investigation: The SEC and U.S. Attorney's Office are investigating historical stock option granting practices. A related shareholder derivative lawsuit was settled in April 2008 for $1.5 million (covered by insurance).
- Corporate Integrity Agreement: The company is under a five-year agreement with the Office of Inspector General (OIG) following a 2006 settlement regarding billing practices. Failure to comply could result in exclusion from federal healthcare programs.
- Reimbursement Risk: Potential reductions in Medicare fee schedules and state budget shortfalls affecting Medicaid funding pose risks to future revenue.
- Capital Markets: Disruptions in credit markets could affect the company's ability to access its line of credit, which is used to fund acquisitions and liquidity needs.
Investor Verification Checklist
- Recurring vs. Non-Recurring Income: Verify the sustainability of net income growth by excluding the $22.0 million gain from the sale of the discontinued laboratory business.
- Liquidity Position: Assess the impact of the $139.5 million draw on the line of credit and the negative working capital position on future operational flexibility.
- Payor Mix Trends: Monitor the shift toward government payors and its potential long-term effect on reimbursement rates and operating margins.
- Regulatory Outcomes: Track the status of the SEC investigation into stock option practices and any potential penalties or restatements.
- Acquisition Integration: Evaluate the performance of the 13 physician groups acquired in 2008, particularly the new anesthesia practices, to ensure they meet projected margin improvements.